112 related articles for article (PubMed ID: 22116018)
21. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer.
Kranzfelder M; Schuster T; Geinitz H; Friess H; Büchler P
Br J Surg; 2011 Jun; 98(6):768-83. PubMed ID: 21462364
[TBL] [Abstract][Full Text] [Related]
22. Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma.
Thallinger CM; Kiesewetter B; Raderer M; Hejna M
Anticancer Res; 2012 Nov; 32(11):4609-27. PubMed ID: 23155224
[TBL] [Abstract][Full Text] [Related]
23. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence.
Pöttgen C; Eberhardt W; Stamatis G; Stuschke M
Oncotarget; 2017 Jun; 8(25):41670-41678. PubMed ID: 28415831
[TBL] [Abstract][Full Text] [Related]
24. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis.
Luo HS; Huang HC; Lin LX
Radiat Oncol; 2019 Oct; 14(1):178. PubMed ID: 31623639
[TBL] [Abstract][Full Text] [Related]
25. Combined-modality treatment of esophageal cancer.
Urba S
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 9):63-7. PubMed ID: 9330411
[TBL] [Abstract][Full Text] [Related]
26. Role of adjuvant chemoradiotherapy in treatment of resectable esophageal carcinoma: a meta-analysis.
Zheng B; Zheng W; Zhu Y; Lin XY; Xu BH; Chen C
Chin Med J (Engl); 2013 Mar; 126(6):1178-82. PubMed ID: 23506601
[TBL] [Abstract][Full Text] [Related]
27. Preoperative radiotherapy for esophageal carcinoma. Oeosphageal Cancer Collaborative Group.
Arnott SJ; Duncan W; Gignoux M; Girling DJ; Hansen HS; Launois B; Nygaard K; Parmar MK; Rousell A; Spiliopoulos G; Stewart LA; Tierney JF; Wang M; Rhugang Z
Cochrane Database Syst Rev; 2000; (2):CD001799. PubMed ID: 10796823
[TBL] [Abstract][Full Text] [Related]
28. [Combined-modality therapy for locoregional esophageal cancer].
Kim SB
Korean J Gastroenterol; 2004 Oct; 44(4):179-85. PubMed ID: 15505428
[TBL] [Abstract][Full Text] [Related]
29. Multimodality approaches for the curative treatment of esophageal cancer.
Jang R; Darling G; Wong RK
J Natl Compr Canc Netw; 2015 Feb; 13(2):229-38. PubMed ID: 25691613
[TBL] [Abstract][Full Text] [Related]
30. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group).
Arnott SJ; Duncan W; Gignoux M; Girling DJ; Hansen HS; Launois B; Nygaard K; Parmar MK; Roussel A; Spiliopoulos G; Stewart LA; Tierney JF; Mei W; Rugang Z
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):579-83. PubMed ID: 9635705
[TBL] [Abstract][Full Text] [Related]
31. Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis.
Sun L; Zhao F; Zeng Y; Yi C
Med Sci Monit; 2017 Feb; 23():889-910. PubMed ID: 28214903
[TBL] [Abstract][Full Text] [Related]
32. Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review.
Xiao L; Czito BG; Pang Q; Hui Z; Jing S; Shan B; Wang J
J Cancer; 2020; 11(15):4605-4613. PubMed ID: 32489478
[No Abstract] [Full Text] [Related]
33. Reporting outcomes of definitive radiation-based treatment for esophageal cancer: a review of the literature.
Main BG; Strong S; McNair AG; Falk SJ; Crosby T; Blazeby JM
Dis Esophagus; 2015; 28(2):156-63. PubMed ID: 24438540
[TBL] [Abstract][Full Text] [Related]
34. Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments.
Procopio F; Marano S; Gentile D; Da Roit A; Basato S; Riva P; De Vita F; Torzilli G; Castoro C
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861604
[TBL] [Abstract][Full Text] [Related]
35. [Radiotherapy dose escalation does not improve local control in patients with esophageal cancer after definitive radiochemotherapy: the ARTDECO randomized phase III trial].
Fokas E; Martin D; Rödel C
Strahlenther Onkol; 2022 Apr; 198(4):397-399. PubMed ID: 35166870
[No Abstract] [Full Text] [Related]
36. Is surgery necessary with multimodality treatment of oesophageal cancer.
O'Reilly S; Forastiere AA
Ann Oncol; 1995 Jul; 6(6):519-21. PubMed ID: 8573528
[No Abstract] [Full Text] [Related]
37. Factors Influencing Compliance to Radical Treatment of Middle Thoracic Esophageal Cancer: An Audit from a Regional Cancer Centre.
Kapoor R; Bansal A; Kumar S; Miriyala RT
Indian J Palliat Care; 2016; 22(3):288-94. PubMed ID: 27559257
[TBL] [Abstract][Full Text] [Related]
38. Bayesian interim analysis of randomised trials.
Fayers P
Lancet; 1997 Jun; 349(9069):1911. PubMed ID: 9217778
[No Abstract] [Full Text] [Related]
39. Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.
Porschen R; Fischbach W; Gockel I; Hollerbach S; Hölscher A; Jansen PL; Miehlke S; Pech O; Stahl M; Vanhoefer U; Ebert MPA
United European Gastroenterol J; 2024 Apr; 12(3):399-411. PubMed ID: 38284661
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial.
Lin Y; Liang HW; Liu Y; Pan XB
Front Immunol; 2023; 14():1264912. PubMed ID: 37860010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
